EXAS250117C82500
- 0.05
- -0.10-66.67%
Exact Sciences Newsroom
Exact Sciences Corporation (NASDAQ:EXAS) Is Expected To Breakeven In The Near Future
Exact Sciences: Strong Screening Revenue Growth and Strategic Initiatives Justify Buy Rating
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $65 to $86
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Exact Sciences Price Target Maintained With a $65.00/Share by Benchmark
Exact Sciences Analyst Ratings
Craig-Hallum Sticks to Their Buy Rating for Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Exact Sciences (EXAS) and Exelixis (EXEL)
Exact Sciences Boosts Finances and Plans New Launches
Express News | Exact Sciences Corp - Enters Into Senior Secured Revolving Credit Agreement
Analysts Conflicted on These Healthcare Names: Tilray (TLRY) and Exact Sciences (EXAS)
Exact Sciences (EXAS) Gets a Buy From TD Cowen
BofA Securities Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $72
Exact Sciences' Strong Q4 Performance and Growth Prospects Justify Buy Rating
Citi Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Express News | Exact Sciences Corp - Expects Q4 2024 Revenue of $713 Million
Press Release: Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
Medicare Drug Prices Nearly Double, Surpassing Inflation: AARP
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not